Announcements Trials

Browse Landscape

Phase

Phase 2 10 Phase 1/2 6 Phase 3 4 Phase 1 3 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 3 Pancreatic Neoplasms 3 Breast Neoplasms 3 Thymoma 1 Thymic epithelial tumor 1 Squamous NSCLC 1 Mediastinal Neoplasms 1 Lung Neoplasms 1 Gallbladder Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1 Advanced Gastric or Gastroesophageal Junction Adenocarcinoma 1

Interventions

Cisplatin 6 Pemetrexed 5 Carboplatin 5 pembrolizumab 4 Paclitaxel 4 Magnetic Resonance Spectroscopy 4 Docetaxel 4 Gemcitabine 3 Dexamethasone 3 dexamethasone acetate 2 dexamethasone 21-phosphate 2 cemiplimab 2 auricularum 2 Specimen Handling 2 Ramucirumab 2 Radiotherapy 2 Leucovorin 2 Erlotinib Hydrochloride 2 Drug Therapy 2 Calcium Dobesilate 2 pertuzumab 1 oblimersen 1 maimendongtang 1 endostar protein 1 cyclopropapyrroloindole 1 cediranib 1 aumolertinib 1 anamorelin 1 Vitamin B 12 1 Vinorelbine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Lung Neoplasms × 130-nm albumin-bound paclitaxel × Clear all

NCT07063745 2026-05-18

MountainTAP-29

Bristol-Myers Squibb

Phase 2/3 Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡